TABLE 3.
Comparison of treatment duration and demographic and clinical characteristics of the three treatment cohorts in S‐MHC (N = 1040)
| Relative to COVID‐19 | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Prior | Partially | Entirely | |||||||
| 1374 | 735 | 256 | 2374 | ||||||
| Initial sample size (N) | N | % | N | % | N | % | χ 2(2) | p | |
| Treatment dropouts | 183 | 13.3 | 48 | 6.5 | 36 | 13.6 | 10.03 | .007 | |
| ROM response | 551 | 40.1 | 355 | 48.3 | 134 | 50.6 | 18.61 | <.001 | 1 < 2 < 3 |
| M | SD | M | SD | M | SD | F(2) | p | Post hoc | |
| Age | 36.9 | 12.5 | 35.3 | 12.1 | 37.0 | 13.0 | 2.17 | .12 | 1 = 2 = 3 |
| Pretest severity (OQ‐SD) | 56.7 | 15.3 | 57.0 | 14.0 | 56.8 | 14.3 | 0.07 | .93 | 1 = 2 = 3 |
| Functioning (GAF) | 56.1 | 5.6 | 55.1 | 5.4 | 54.6 | 4.0 | 6.51 | .002 | 1 > 2, 1 > 3, 2 = 3 |
| N | % | N | % | N | % | χ 2(2) | p | ||
| Female gender | 373 | 62.5% | 228 | 64.2% | 99 | 73.9% | 6.22 | .045 | 1 = 2 < 3 |
| Diagnosis | N | % | N | % | N | % | χ 2(12) | p | |
| Depression | 332 | 55.6% | 195 | 54.9% | 65 | 48.5% | 29.82 | .003 | 1 = 2 > 3 |
| Anxiety | 150 | 25.1% | 94 | 26.5% | 39 | 29.1% | 1 = 2 < 3 | ||
| PTSD | 4 | 0.7% | 2 | 0.6% | 3 | 2.2% | 1 = 2 < 3 | ||
| Adjustment disorder | 3 | 0.5% | 3 | 0.8% | 1 | 0.7% | |||
| Pers disorder | 4 | 0.7% | 4 | 1.1% | 6 | 4.5% | |||
| Psychotic disorder | 57 | 9.5% | 21 | 5.9% | 16 | 11.9% | |||
| Other | 47 | 7.9% | 36 | 10.1% | 4 | 3.0% | |||
| Comorbidity | N | % | N | % | N | % | χ 2(6) | p | |
| No comorbidity | 259 | 43.4% | 144 | 40.6% | 46 | 34.3% | 3.86 | .43 | 1 = 2 = 3 |
| Axis 1 comorbidity | 297 | 49.7% | 186 | 52.4% | 77 | 57.5% | |||
| Axis 2 comorbidity | 41 | 6.9% | 25 | 7.0% | 11 | 8.2% | |||
| M | SD | M | SD | M | SD | F(2) | p | Post hoc | |
| Number of sessions | 54.6 | 31.6 | 67.5 | 41.3 | 51.4 | 32.6 | 19.9 | <.001 | 2 > 1, 2 > 3, 1 = 3 |
| Mean treatment duration | 279.4 | 85.3 | 325.6 | 60.9 | 224.7 | 91.5 | 86.65 | <.001 | 2 > 1, 2 > 3, 1 > 3 |